Cervix Cancer, Endometrial Cancer
Conditions
Keywords
Cervical Cancer, Endometrical Cancer ,Gastrointestinal & Genitourinary toxicities
Brief summary
Cervical cancer is the 4th most common cancer in women globally and the 2nd most common in India. In India, between 2018 and 2020, cervical cancer saw a surge of 26,985 from 2018 to 2020. The treatment for cervical cancer depends on the clinical stage. Treatment of early stage cervical cancer (Stage IB1-IIA) includes chemo-radiation or surgery +/- adjuvant (CT)RT and VBT if indicated. The choice of adjuvant treatment relies on identifying specific risk factors. Patients fulfilling Sedli's intermediate-risk criteria, requires pelvic radiotherapy alone and patients with high-risk Peter's criteria, require adjuvant chemoradiation. This risk-based approach helps tailor adjuvant therapies to individual patient. India reported 16,413 new cases and 6,385 deaths of endometrial cancer, with a mortality rate of 0.73%. The primary treatment for endometrial carcinoma is total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO). The Adjuvant treatment depends on risk stratification group according to ESGO/ESTRO/ESP guidelines determined through molecular-based risk stratification. Adjuvant treatment includes radiotherapy, chemotherapy, and brachytherapy. To reduce the burden of acute and late toxicity, advanced external radiation techniques like image guided intensity modulated radiotherapy (IG IMRT) are used. IG IMRT have shown their potential to reduce late toxicity in long term survivors compared to 3DCRT technique. Since January 2020, our institution (TATA memorial centre, Mumbai) has incorporated routine IG-IMRT (Image-Guided Intensity-Modulated Radiation Therapy) for treatment of cervical and endometrial cancer. However, no post-implementation assessment of treatment outcomes and potential toxicity has occurred. This is retrospective observational study aims to evaluate the clinical application of IG-IMRT. Primary aim of this study is to audit the 3 years incidence of ≥ grade II Gastrointestinal & Genitourinary toxicities in women receiving Adjuvant IMRT (with or without chemotherapy) between January 2020 to June 2023
Interventions
None listed
Sponsors
Tata Memorial Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients more than 18 years of age at the time of diagnosis. * All patients with confirmed histological diagnosis of cervical or endometrial cancer. * Only those patients who have received adjuvant (chemo)radiotherapy with IMRT and/or brachytherapy at TMH/ACTREC will be included. * Patients whose follow up information available
Exclusion criteria
* Patients with incomplete treatment details. * Patient having residual disease post-surgery. * Patient treated for post-operative recurrences. * Patient who lost to follow up. * Patients with Immunosuppressive disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3 years incidence of ≥ grade II Gastrointestinal & Genitourinary toxicities | 3 years | To audit the 3 years incidence of ≥ grade II Gastrointestinal \& Genitourinary toxicities in women receiving Adjuvant IMRT (with or without chemotherapy) for cervical and endometrial cancer between January 2020 to December 2023 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Report acute toxicity in patients receiving adjuvant RT | 3 years | To report acute toxicity in patients receiving adjuvant RT from the time of treatment completion till 3 years |
| Assess disease free and overall survival (for cervix and endometrial cancer separately). | 3 Years | To assess 3-year disease free and overall survival (for cervix and endometrial cancer separately) from the time of treatment completion to 3 years |
| Assess local regional control | 3 Years | To assess 3 years local regional control from the time of treatment completion till 3 years |
| Report dose-volume parameters for prediction of late grades II-IV gastrointestinal and genitourinary toxicity | 3 Years | Report dose-volume parameters for prediction of late grades II-IV gastrointestinal and genitourinary toxicity from treatment completion till 3 years |
| compare outcomes with ongoing and completed institutional postoperative IMRT trials | 3 Years | To compare outcomes with ongoing and completed institutional postoperative IMRT trials from the time of treatment completion to 3 years |
Countries
India
Contacts
CONTACTSupriya Chopra
Outcome results
None listed